Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 671-681, March 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traganos, F.
Right arrow Articles by Melamed, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traganos, F.
Right arrow Articles by Melamed, M. R.

Action of Dihydroxyanthraquinone on Cell Cycle Progression and Survival of a Variety of Cultured Mammalian Cells1

Frank Traganos2, Donald P. Evenson, Lisa Staiano-Coico, Zbigniew Darzynkiewicz and Myron R. Melamed

Investigative Cytology Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Dihydroxyanthraquinone, 1,4-dihydroxy-5,8-bis{{{2-[(2-hydroxyethyl)amino]ethyl}amino}}-9,10-anthracenedione (NSC 279836), was observed to alter the cell cycle kinetics of a variety of mammalian cell lines as monitored by flow cytometry. Continuous exposure of Friend leukemia, L1210, and Chinese hamster cells to the drug in vitro at concentrations of 1.0 to 10 ng/ml resulted in the accumulation of cells in G2 by 24 hr in culture. When cells were exposed to dihydroxyanthraquinone for 30 min, washed free of drug, and cultured in fresh medium for 24 hr, a 10 times higher drug concentration was required to produce a G2 block identical to that observed during continuous exposure. Stimulation of human lymphocytes by phytohemagglutinin could be inhibited in a dose-dependent manner by brief pretreatment of cells with the drug. However, while previously stimulated but as yet noncycling lymphocytes were profoundly affected by much lower concentrations, proliferating lymphocytes were refractory to treatment with the drug up to a concentration of 1 µg/ml.

Exposure to the drug for 24 hr, at concentrations as low as 3.2 ng/ml, inhibited colony formation of exponentially growing Chinese hamster cells by 50%, whereas stationary culture required an 8-fold higher concentration to produce the same results. Drug concentrations in the range of 0.3 to 0.8 µg/ml over a period of 24 hr reduced the viability of Friend leukemia and L1210 cells by 50% as measured by trypan blue dye exclusion. In contrast, human lymphocyte viability was only mildly affected following 24 hr incubation with up to 5.0 µg dihydroxyanthraquinone per ml.

There was a marked effect on cellular RNA content in two of the cell lines tested. Friend leukemia and L1210 cells blocked in G2 by the drug manifested a 140 and 70% increase in RNA content, respectively, when compared to control cells. In addition, though suboptimal concentrations of the drug resulted in a transient accumulation of cells in G2, optimal drug concentrations not only blocked cells in G2 but in the case of Friend leukemia and L1210 cells led to an increase in the proportion of cells with greater than 4C amounts of DNA.

The results obtained with dihydroxyanthraquinone were compared to those obtained previously with a nonhydroxylated analog, anthracenedione (NCS 287513).

1 Supported by Grant CA23296-01 from the National Cancer Institute and in part by NCI Core Grant CA-08748.

2 To whom requests for reprints should be addressed, at Investigative Cytology Laboratory, Memorial-Sloan-Kettering Cancer Center, 1275 York Avenue, New York, N. Y. 10021.

Received 5/21/79. Accepted 12/ 5/79.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.